Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for AD Compared With Medicare Beneficiaries With AD and MCI

This study evaluates whether patients enrolled in trials of aducanumab, EMERGE and ENGAGE, were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with Alzheimer disease (AD) or mild cognitive impairment (MCI) who would have been excluded from these trials.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research